ライフサイエンスコーパス: cardiovascular disease

1 ssociates with obesity, type 2 diabetes, and cardiovascular disease.

2 L) seem altered in patients with symptomatic cardiovascular disease.

3 y in adulthood interact to predict events of cardiovascular disease.

4 unteract the high morbidity and mortality of cardiovascular disease.

5 ase the emphasis on chronic diseases such as cardiovascular disease.

6 assess whether AKI associates with long-term cardiovascular disease.

7 rturbation of CL metabolism is implicated in cardiovascular disease.

8 diseases, skin cancer, prostate cancer, and cardiovascular disease.

9 r cells (MDSC) and are at increased risk for cardiovascular disease.

10 eath and coronary events in patients without cardiovascular disease.

11 tive and therapeutic approaches for treating cardiovascular disease.

12 hypertension, type 2 diabetes mellitus, and cardiovascular disease.

13 tential biomarker in selected pathologies of cardiovascular disease.

14 erent explanation for population patterns in cardiovascular disease.

15 ctively consider and treat all patients with cardiovascular disease.

16 ts potential as a therapeutic target against cardiovascular disease.

17 alt consumption can lead to hypertension and cardiovascular disease.

18 is particularly pronounced in patients with cardiovascular disease.

19 onal relevance of impaired CgA processing in cardiovascular disease.

20 ayed a protective role in the development of cardiovascular disease.

21 te patient cohorts (587 total patients) with cardiovascular disease.

22 iction and diagnostics for the management of cardiovascular disease.

23 y higher risk of developing hypertension and cardiovascular disease.

24 es with an increased risk of atherosclerotic cardiovascular disease.

25 circulating noncoding RNAs as biomarkers in cardiovascular disease.

26 an be used to improve treatment planning for cardiovascular disease.

27 p apnea is highly prevalent in patients with cardiovascular disease.

28 uman immunodeficiency virus (HIV)-associated cardiovascular disease.

29 tion, all of which are critical mediators of cardiovascular disease.

30 ies covering the role of oxidative stress in cardiovascular disease.

31 on the gut microbiota and the prevention of cardiovascular disease.

32 Obesity is a known risk factor for cardiovascular disease.

33 nd diastolic dysfunction are associated with cardiovascular disease.

34 reased risk of diabetes, kidney disease, and cardiovascular disease.

35 established risk factor for atherosclerotic cardiovascular disease.

36 nvironment and pollution have been linked to cardiovascular disease.

37 e endorsed aspirin for primary prevention of cardiovascular disease.

38 arker combinations pivotal for understanding cardiovascular disease.

39 nel blocker clinically used in patients with cardiovascular disease.

40 in patients with established atherosclerotic cardiovascular disease.

41 vated threefold to fourfold in patients with cardiovascular disease.

42 omes for patients with diabetes mellitus and cardiovascular disease.

43 mation and thereby preventing CKD-associated cardiovascular disease.

44 nd summarize the data linking epigenetics to cardiovascular disease.

45 duced perinatal nutrition programmes chronic cardiovascular disease.

46 incident type 2 diabetes and atherosclerotic cardiovascular disease.

47 ions, and to explore how these contribute to cardiovascular disease.

48 Parkinson's disease, multiple sclerosis and cardiovascular disease.

49 inuria, long-term risk factors for renal and cardiovascular disease.

50 men, diabetic women are at a higher risk of cardiovascular disease.

51 death/myocardial infarction in patients with cardiovascular disease.

52 ce, education, smoking status, diabetes, and cardiovascular disease.

53 ta2AR, whose ligands are used for asthma and cardiovascular disease.

54 rotective with respect to obesity-associated cardiovascular disease.

55 a cohort of 351 adults at risk for ischemic cardiovascular disease.

56 sympathetic nervous activity underlies many cardiovascular diseases.

57 for longitudinal epidemiological studies in cardiovascular diseases.

58 role in human health and disease, including cardiovascular diseases.

59 l aging and to various neurodegenerative and cardiovascular diseases.

60 ions mediated by 20-HETE in hypertension and cardiovascular diseases.

61 t for heart failure, hypertension, and other cardiovascular diseases.

62 posed as novel prognostic factors in several cardiovascular diseases.

63 in various cancers, congenital defects, and cardiovascular diseases.

64 s been causally linked to the development of cardiovascular diseases.

65 al significance of genetic variants in human cardiovascular diseases.

66 ovel therapeutic option for the treatment of cardiovascular diseases.

67 lot from the successes in the prevention of cardiovascular diseases.

68 iomarkers has raised significant interest in cardiovascular diseases.

69 recognized innate immune sensor involved in cardiovascular diseases.

70 seases.The gut microbiota may play a role in cardiovascular diseases.

71 ion as alternative therapeutics for managing cardiovascular diseases.

72 it damage associated with the progression of cardiovascular diseases.

73 bA1c clinical categories for atherosclerotic cardiovascular disease, 0.701 for ADA fasting glucose co

74 idence rate ratio, 1.48; 95% CI, 1.37-1.59), cardiovascular disease (1.20; 95% CI, 1.06-1.36), depres

75 hypertensive heart disease, and 99815 other cardiovascular disease), 128294 from stroke (16125 ische

76 r (25%), infectious complications (25%), and cardiovascular disease (21.9%).

77 ce interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); d

78 CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1).

79 We found that cardiovascular disease admissions decreased by 32% on hi

80 rs for ADHF included chronic kidney disease, cardiovascular disease, age>/=75 years, body mass index,

81 ns and is largely attributable to death from cardiovascular disease, although cancer incidence and mo

82 uggest calcium could have adverse effects on cardiovascular disease, although these findings are cont

83 miR expression has been associated with many cardiovascular diseases; although their contributory rol

84 el in blood over 500mg/dL is a biomarker for cardiovascular diseases, Alzheimer disease, pancreatitis

85 lowering LDL-C for the primary prevention of cardiovascular disease among individuals with primary el

86 hood is an especially strong risk factor for cardiovascular disease among those small at birth.

87 prospective association of CAC with risk of cardiovascular disease and all-cause mortality among dia

88 e association of CAC with subsequent risk of cardiovascular disease and all-cause mortality in this p

89 eing is associated with an increased risk of cardiovascular disease and arrhythmias, with the most co

90 correlated with various diseases, including cardiovascular disease and cancer.

91 T2 inhibitor use was associated with reduced cardiovascular disease and cardiovascular mortality comp

92 antagonists-is proposed as a way of reducing cardiovascular disease and combating a leading cause of

93 with a personal medical history of cancer or cardiovascular disease and death by casualty were exclud

94 s a cluster of interrelated risk factors for cardiovascular disease and diabetes mellitus.

95 profoundly impacts human health, increasing cardiovascular disease and diabetes risk, yet the underl

96 stools from individuals with atherosclerotic cardiovascular disease and healthy controls, identifying

97 They also had significantly higher rates of cardiovascular disease and hypotension.

98 tems will help us decipher the complexity of cardiovascular disease and monitor novel therapeutic str

99 e, age 46 +/- 14 years), no prior history of cardiovascular disease and normal systolic blood pressur

100 d are at risk of developing type 2 diabetes, cardiovascular disease and related metabolic and inflamm

101 ession in 401 participants free of prevalent cardiovascular disease and risk factors.

102 The prespecified primary outcome was cardiovascular disease and secondary outcomes were respi

103 hospitalization was found, in particular for cardiovascular diseases and diabetes mellitus.

104 m to be specific for AAA compared with other cardiovascular diseases and related traits suggesting th

105 versus </=high school); more likely to have cardiovascular diseases and risk factors (ORadj's = 1.1-

106 t evaluation for multiple systemic potential cardiovascular diseases and their risk factors.

107 kocyte telomere length (LTL) with all-cause, cardiovascular disease, and cancer mortality in 12,199 a

108 ith cardiometabolic risk factors, history of cardiovascular disease, and cerebrovascular pathology.A

109 s with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.

110 susceptibility to the development of cancer, cardiovascular disease, and diabetes has not been formal

111 sociation of arsenic metabolism with cancer, cardiovascular disease, and diabetes-related outcomes in

112 poor self-reported general health, incident cardiovascular disease, and incident cancer.

113 pe 1 and type 2 diabetes, hepatic steatosis, cardiovascular disease, and inflammatory bowel diseases.

114 with increased risk of target organ damage, cardiovascular disease, and mortality.

115 h nonelevated clinic BP, no history of overt cardiovascular disease, and no use of antihypertensive m

116 ith cardiometabolic risk factors, history of cardiovascular disease, and radiologic evidence of cereb

117 ection, prior osteonecrosis, prior fracture, cardiovascular disease, and recent non-AIDS cancer (last

118 FAs) is associated with an increased risk of cardiovascular disease, and reducing their consumption i

119 mmon risk factors, biomarkers, and prevalent cardiovascular disease, and their attributable risk by s

120 us and prediabetes, patients at high risk of cardiovascular disease, and those with prevalent coronar

121 d blood proteins related to inflammation and cardiovascular disease archived from a phase 3 clinical

122 anations for these persistent disparities in cardiovascular disease are multifactorial and span from

123 tics, preventive strategies, and therapy for cardiovascular disease are reviewed.

124 Pharmacological therapies for cardiovascular diseases are limited by short-term pharma

125 Cardiovascular diseases are the leading cause of fatalit

126 alcium (CAC) score, incident atherosclerotic cardiovascular disease (ASCVD) events, and atrial fibril

127 Atherosclerotic cardiovascular disease (ASCVD) is associated with signif

128 age, other discriminators of atherosclerotic cardiovascular disease (ASCVD) risk are needed in older

129 The use of atherosclerotic cardiovascular disease (ASCVD) risk to personalize systo

130 In patients with atherosclerotic cardiovascular disease (ASCVD), guidelines recommend opt

131 ximately 97% of patients had atherosclerotic cardiovascular disease (ASCVD).

132 those at increased risk for atherosclerotic cardiovascular disease (ASCVD).

133 ith subclinical and clinical atherosclerotic cardiovascular disease (ASCVD).

134 The primary cause of death is cardiovascular disease at about 14 years.

135 t CHD cases and 1,621 controls free of major cardiovascular disease at baseline and follow-up visits

136 There were 1541 participants without cardiovascular disease at baseline who had CAC scores.

137 in a multiethnic population free of clinical cardiovascular disease at baseline.

138 8 countries with diabetes mellitus and known cardiovascular disease at entry into TECOS (Trial Evalua

139 se mutations developed prominent and similar cardiovascular disease at similar ages, despite markedly

140 educed LDL receptor function, xanthomas, and cardiovascular disease before age 20 years.

141 or gender, age, education, family history of cardiovascular diseases, body mass index, diabetes, smok

142 ence are sentinels for the future population cardiovascular disease burden.

143 ssel cerebral vascular disease or history of cardiovascular disease but lower odds of small-vessel ce

144 trates are commonly used in the treatment of cardiovascular disease, but clinical data limit their us

145 tus is associated with an increased risk for cardiovascular disease, but the link between hyperglycem

146 association between CHIP and atherosclerotic cardiovascular disease, but the nature of this associati

147 es in host physiology and the development of cardiovascular diseases, but the microbiota-triggered pa

148 CHGA is dysregulated in several cardiovascular diseases, but the underlying mechanisms a

149 timate age-standardized mortality rates from cardiovascular diseases by county.

150 Underlying disease states such as cardiovascular disease can alter the biological milieu p

151 ith several age-related disorders, including cardiovascular disease, cancer, decline in cognitive fun

152 Current cardiovascular disease care innovations in informatics,

153 For other cardiovascular disease causes, the ratio ranged from 1.4

154 subgroups in SPRINT: age >/=75 years, prior cardiovascular disease, chronic kidney disease, women, b

155 isorders (cancers, diabetes, sleep disorder, cardiovascular diseases, chronic lower respiratory tract

156 gher risk of being hospitalized and dying of cardiovascular disease compared with the general populat

157 855 men, mean age: 47.8+/-3.5 years) free of cardiovascular diseases completed the Center of Epidemio

158 Several cardiovascular disease conditions were clustered substan

159 take of total and specific types of nuts and cardiovascular disease, coronary heart disease, and stro

160 In total, 314 cases of incident cardiovascular disease (CVD) (myocardial infarction, uns

161 studies have reported increased incidence of cardiovascular disease (CVD) among individuals with low

162 The lack of research to characterize cardiovascular disease (CVD) and CVD risk factors in tra

163 e association of dog ownership with incident cardiovascular disease (CVD) and death in a register-bas

164 nal associations between red meat intake and cardiovascular disease (CVD) are inconsistent.

165 ducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lo

166 Few data are available comparing cardiovascular disease (CVD) biomarker profiles between

167 nents in young adulthood optimally determine cardiovascular disease (CVD) by middle age.

168 Cardiovascular disease (CVD) complications are important

169 ers [blood pressure within sodium intake and cardiovascular disease (CVD) context and low density lip

170 nts with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertrigl

171 luates low-fat dietary pattern influences on cardiovascular disease (CVD) incidence and mortality dur

172 er of SE alleles (0, 1, or 2) with total and cardiovascular disease (CVD) mortality and incident coro

173 Worldwide implementation of risk-based cardiovascular disease (CVD) prevention requires risk pr

174 evels with ischaemic heart disease (IHD) and cardiovascular disease (CVD) risk factors are inconsiste

175 populations from sub-Saharan Africa, adverse cardiovascular disease (CVD) risk factors have been obse

176 sure and cholesterol measurements to predict cardiovascular disease (CVD) risk has not been rigorousl

177 cardiovascular risk factors and subclinical cardiovascular disease (CVD) with the hypothesis that pe

178 gression of diabetic vascular complications, cardiovascular disease (CVD), and cancer progression and

179 hown to be associated with increased risk of cardiovascular disease (CVD), but it is unknown whether

180 Medication nonadherence, a major problem in cardiovascular disease (CVD), contributes yearly to appr

181 Aging, the main risk factor for cardiovascular disease (CVD), is becoming progressively

182 sclerosis), a cohort initially free of overt cardiovascular disease (CVD).

183 weight (BW) and waist circumference (WC) on cardiovascular disease (CVD).

184 dominant disorder associated with premature cardiovascular disease (CVD).

185 diabetic rodents, inhibition of MGO prevents cardiovascular disease (CVD).

186 between the Mediterranean diet (MedDiet) and cardiovascular disease (CVD).We evaluated the associatio

187 ted foods have been shown to protect against cardiovascular disease (CVD).We investigated the associa

188 4,952 men died, of which 1,637 men died from cardiovascular diseases (CVD), 2,122 from cancer during

189 rview of the current epidemiological data on cardiovascular diseases (CVD), its risk factors, and des

190 associated with the risk for and outcome of cardiovascular diseases (CVDs).

191 alth infrastructure to include management of cardiovascular disease, developing global partners and p

192 ntribute to a variety of diseases, including cardiovascular disease, diabetes, and cancer.

193 ding to hospitalizations and the presence of cardiovascular disease, diabetes, testicular cancer, or

194 These traits are risk factors for cardiovascular disease even below the diabetic threshold

195 in the longitudinal study, 22 of whom had a cardiovascular disease event during median follow-up of

196 Understanding the relative contributions of cardiovascular disease event types to the excess burden

197 transporter (ABCG1; P=7.2E-28) and incident cardiovascular disease events (hazard ratio per SD incre

198 inflammation (r=0.49; p<0.0001), and risk of cardiovascular disease events (standardised hazard ratio

199 ve systolic blood-pressure control prevented cardiovascular disease events and prolonged life and did

200 nd monitoring in patients with hypertension, cardiovascular disease events and subsequent treatment c

201 Relations between amygdalar activity and cardiovascular disease events were assessed with Cox mod

202 7.4 years (5.5-9.3) of follow-up, 4784 major cardiovascular disease events, 1649 cardiovascular death

203 ne DBP was associated with increased risk of cardiovascular disease events, but there was no evidence

204 risk of post-traumatic stress disorder after cardiovascular disease events.

205 ificant cCIMT-LEA associations with clinical cardiovascular disease events.

206 ortions, and both increase the prevalence of cardiovascular disease events.

207 rs or more after diagnosis of breast cancer, cardiovascular disease exceeded breast cancer as the lea

208 visceral adipose tissue, and 10-year global cardiovascular disease Framingham risk, and it provided

209 ers measured twice, 10 to 16 years apart, in cardiovascular disease-free women, considering either av

210 We pooled participants without prevalent cardiovascular disease from 3 community-based cohort stu

211 335 individuals aged 35 to 70 years without cardiovascular disease from 613 communities in 18 low-in

212 The associations between dietary fat and cardiovascular disease have been evaluated in several st

213 apacity of the gut microbiome in relation to cardiovascular diseases have not been systematically exa

214 1.5, 95% confidence interval: 1.4, 1.6) and cardiovascular disease (hazard ratio = 1.4, 95% confiden

215 ths before enrolment, clinically significant cardiovascular disease, hepatitis B or hepatitis C viral

216 aldosterone increase the risk for developing cardiovascular disease; however, the influence of aging

217 Early-stage breast cancer, age, cardiovascular disease, hypertension, and diabetes.

218 oor and increase risk of developing obesity, cardiovascular disease, hypertension, obesity-related ca

219 ls and 4 different presentations of incident cardiovascular disease in a contemporary population.

220 that likely contributes to the high rates of cardiovascular disease in HIV-infected individuals.

221 of cardiovascular dysfunction and programme cardiovascular disease in later life.

222 soriasis-like skin disease and also improves cardiovascular disease in mice.

223 ng is a valuable tool for managing inherited cardiovascular disease in patients and families, includi

224 Cardiovascular disease in patients with breast cancer is

225 able therapy for preventing fetal origins of cardiovascular disease in pregnancy complicated by chron

226 e development of endothelial dysfunction and cardiovascular disease in SLE.

227 e cohort of middle-aged men with subclinical cardiovascular disease in the Aragon Workers' Health Stu

228 ith type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Em

229 The Cardiovascular Disease in Women Committee of the America

230 been linked with the development of various cardiovascular diseases in otherwise healthy individuals

231 o improve end-of-life care for patients with cardiovascular disease include optimizing metrics to ass

232 Incidence of cardiovascular disease (including myocardial infarction,

233 derscore a potential genetic risk factor for cardiovascular diseases, including stroke.

234 t mice is sufficient to elicit age-dependent cardiovascular disease involving premature calcification

235 Cardiovascular disease is a leading cause of death among

236 Atherosclerotic cardiovascular disease is a leading cause of death in th

237 Cardiovascular disease is associated with epigenomic cha

238 disease event types to the excess burden of cardiovascular disease is important for developing effec

239 variation underlying many heritable forms of cardiovascular disease is incompletely understood, even

240 lipid and signaling molecule associated with cardiovascular disease, is known to activate extracellul

241 at the link between vitamin D deficiency and cardiovascular disease may be an epiphenomenon.

242 tice requires (1) recognizing when inherited cardiovascular disease may be present, (2) identifying a

243 molecular targets driving the development of cardiovascular disease, metabolic syndrome, and immune d

244 evidence review conducted for the guideline, cardiovascular disease mortality and colorectal cancer m

245 Age-standardized cardiovascular disease mortality rates by county, year,

246 there was no difference in nonfatal stroke, cardiovascular disease mortality, or all-cause mortality

247 entive effects in atherosclerosis, and other cardiovascular diseases, must be translated into changes

248 n addition, CAC improves risk prediction for cardiovascular disease, myocardial infarction, and heart

249 lated to icatibant occurred in patients with cardiovascular disease, nor in those using icatibant at

250 Cardiovascular disease occurs at lower incidence in prem

251 nd 1.11 (95% CI: 1.04, 1.19) for a composite cardiovascular disease outcome.

252 of metabolites observed in association with cardiovascular disease outcomes.

253 02 (95% CI, 0-0.09; P < .001) for predicting cardiovascular disease over use of all the above-mention

254 ntent, which can have an important impact on cardiovascular disease, particularly in countries where

255 to the understanding of the epidemiology of cardiovascular diseases, particularly stroke.

256 suggested to also potentially contribute to cardiovascular disease pathogenesis.

257 Atherosclerotic cardiovascular disease patients reporting poor versus op

258 with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflo

259 ships between sleep-disordered breathing and cardiovascular disease, presenting clinical and research

260 These findings emphasize that approaches of cardiovascular disease prevention must be directed also

261 tic, diagnostic, and therapeutic options for cardiovascular disease prevention.

262 The constant increase in cardiovascular disease rate coupled with significant dra

263 ecular markers and metabolomic signatures of cardiovascular disease risk (including branched-chain am

264 riglycerides, glucose, and insulin-increases cardiovascular disease risk by inducing oxidative stress

265 rt failure over use of established and novel cardiovascular disease risk factors among patients with

266 was associated with a greater prevalence of cardiovascular disease risk factors and with increased a

267 opment of T2D irrespective of common T2D and cardiovascular disease risk factors by using multiple di

268 rsy surrounds the association of traditional cardiovascular disease risk factors with venous thromboe

269 ice and/or food provision on body weight and cardiovascular disease risk factors.

270 ll the above-mentioned established and novel cardiovascular disease risk factors.

271 efore and after adjustment for lifestyle and cardiovascular disease risk factors.During a follow-up p

272 V and hepatitis C infected people among whom cardiovascular disease risk is elevated and liver diseas

273 The median 10-year atherosclerotic cardiovascular disease risk score of the cohort was 4.8%

274 plasma levels of each of the 156 Framingham Cardiovascular Disease Risk Score-associated proteins us

275 tty acids, which are associated with reduced cardiovascular disease risk.

276 be pathways by which chronic PTSD increases cardiovascular disease risk.

277 of dietary saturated fatty acids (SFAs) and cardiovascular disease risk.We compared the impact of co

278 ; 95% confidence interval (CI): 1.06, 1.53), cardiovascular disease (RR = 1.42; 95% CI: 1.24, 1.63),

279 /10 y; r(2)=0.07; P=1.6x10(-7)) but not with cardiovascular disease severity at baseline.

280 Purpose Cancer and cardiovascular disease share risk factors, and there is

281 usion/(+)sepsis: HR 2.27, 95% CI 1.87-2.76], cardiovascular disease-specific survival [(+)transfusion

282 and prediabetes and those with high risk of cardiovascular disease, stroke, heart failure, and atria

283 ng of different CXCR4-positive cell types in cardiovascular diseases such as atherosclerosis and arte

284 on have a 1.5 to 2 times higher incidence of cardiovascular diseases than their uninfected counterpar

285 fects nearly 1 of 3 women and contributes to cardiovascular disease, the leading cause of death in th

286 h blood pressure is a strong risk factor for cardiovascular disease.The aim of this study was to dete

287 uggested association between periodontal and cardiovascular diseases, this study sought to assess the

288 to clinical data from the Duke Databank for Cardiovascular Disease to compare baseline and procedura

289 participants (45-74 years of age), free from cardiovascular disease until the second visit, risk fact

290 Data suggest that the prediction of adult cardiovascular disease using a model comprised entirely

291 y be on the causal pathway between noise and cardiovascular disease, we examined the influence of lon

292 Subjects with cardiovascular disease were 2.33 times more likely to de

293 dyslipidemia, and diabetes) and preexisting cardiovascular disease were ascertained.

294 Those without prevalent cardiovascular disease were followed until their first C

295 fied in the liver, and those associated with cardiovascular disease were identified in arterial tissu

296 ho were older, male, and had atherosclerotic cardiovascular disease were more likely to be approved,

297 Infections and cardiovascular disease were the cause of death in the ma

298 evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background

299 re among patients with diabetes mellitus and cardiovascular disease, which in turn could lead to redu

300 neous injection in patients at high risk for cardiovascular disease who had elevated LDL cholesterol